Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine
Standard BioTools (NASDAQ: LAB) announced that its SomaScan Platform was instrumental in a Nature Medicine study examining semaglutide's effects on obesity treatment. The research, conducted by Novo Nordisk, analyzed approximately 6,400 human proteins across nearly 2,000 participants from two phase 3 trials.
The study revealed significant changes in protein biomarkers linked to metabolic pathways, providing new insights into semaglutide's biological mechanisms and potential broader health benefits. The SomaScan Technology demonstrated unique advantages, including mechanistic insights into proteins and pathways, reliable results across studies, and the potential to accelerate clinical development through a validated 27-protein predictor that detected cardiovascular benefits in smaller, shorter studies.
Standard BioTools (NASDAQ: LAB) ha annunciato che la sua Piattaforma SomaScan è stata fondamentale in uno studio pubblicato su Nature Medicine che esaminava gli effetti del semaglutide nel trattamento dell'obesità. La ricerca, condotta da Novo Nordisk, ha analizzato circa 6.400 proteine umane su quasi 2.000 partecipanti provenienti da due studi di fase 3.
Lo studio ha rivelato cambiamenti significativi nei biomarcatori proteici legati ai percorsi metabolici, offrendo nuove informazioni sui meccanismi biologici del semaglutide e sui potenziali benefici per la salute. La Tecnologia SomaScan ha dimostrato vantaggi unici, tra cui intuizioni meccanicistiche sulle proteine e sui percorsi, risultati affidabili tra gli studi e la possibilità di accelerare lo sviluppo clinico attraverso un predittore convalidato di 27 proteine che ha rilevato benefici cardiovascolari in studi più piccoli e brevi.
Standard BioTools (NASDAQ: LAB) anunció que su Plataforma SomaScan fue fundamental en un estudio publicado en Nature Medicine que examinó los efectos del semaglutide en el tratamiento de la obesidad. La investigación, realizada por Novo Nordisk, analizó aproximadamente 6,400 proteínas humanas en casi 2,000 participantes de dos ensayos de fase 3.
El estudio reveló cambios significativos en los biomarcadores proteicos relacionados con las rutas metabólicas, proporcionando nuevas perspectivas sobre los mecanismos biológicos del semaglutide y sus posibles beneficios más amplios para la salud. La Tecnología SomaScan demostró ventajas únicas, incluyendo conocimientos mecanicistas sobre proteínas y rutas, resultados confiables a través de estudios, y la posibilidad de acelerar el desarrollo clínico mediante un predictor validado de 27 proteínas que detectó beneficios cardiovasculares en estudios más pequeños y breves.
스탠다드 바이오툴즈 (NASDAQ: LAB)는 소마스캔 플랫폼이 비만 치료에 대한 세마글루타이드의 영향을 조사한 네이처 메디신 연구에서 중요한 역할을 했다고 발표했습니다. 이 연구는 노보 노르디스크에 의해 수행되었으며, 두 개의 3상 시험에 참여한 약 2,000명의 참가자에 대한 약 6,400개의 인간 단백질을 분석했습니다.
이 연구는 대사 경로와 관련된 단백질 바이오마커에서 중요한 변화를 밝혀내어 세마글루타이드의 생물학적 메커니즘과 잠재적인 건강 이점에 대한 새로운 통찰력을 제공합니다. 소마스캔 기술은 단백질과 경로에 대한 메커니즘적 통찰력, 연구 간 신뢰할 수 있는 결과, 그리고 소규모 및 단기 연구에서 심혈관 이점을 감지한 검증된 27개 단백질 예측기를 통해 임상 개발을 가속화할 수 있는 잠재력 등의 고유한 장점을 보여주었습니다.
Standard BioTools (NASDAQ: LAB) a annoncé que sa Plateforme SomaScan a été essentielle dans une étude publiée dans Nature Medicine examinant les effets du sémaglutide sur le traitement de l'obésité. La recherche, menée par Novo Nordisk, a analysé environ 6 400 protéines humaines chez près de 2 000 participants provenant de deux essais de phase 3.
L'étude a révélé des changements significatifs dans les biomarqueurs protéiques liés aux voies métaboliques, offrant de nouvelles perspectives sur les mécanismes biologiques du sémaglutide et ses avantages potentiels pour la santé. La Technologie SomaScan a montré des avantages uniques, y compris des aperçus mécanistes des protéines et des voies, des résultats fiables à travers les études, et le potentiel d'accélérer le développement clinique grâce à un prédicteur validé de 27 protéines qui a détecté des bénéfices cardiovasculaires dans des études plus petites et plus brèves.
Standard BioTools (NASDAQ: LAB) gab bekannt, dass ihre SomaScan-Plattform entscheidend für eine in Nature Medicine veröffentlichte Studie war, die die Auswirkungen von Semaglutid auf die Behandlung von Fettleibigkeit untersuchte. Die Forschung, die von Novo Nordisk durchgeführt wurde, analysierte ungefähr 6.400 menschliche Proteine bei fast 2.000 Teilnehmern aus zwei Phase-3-Studien.
Die Studie zeigte signifikante Veränderungen bei Protein-Biomarkern, die mit metabolischen Wegen verbunden sind, und lieferte neue Einblicke in die biologischen Mechanismen von Semaglutid und mögliche umfassendere gesundheitliche Vorteile. Die SomaScan-Technologie wies einzigartige Vorteile auf, einschließlich mechanistischer Einblicke in Proteine und Wege, zuverlässige Ergebnisse über Studien hinweg und das Potenzial, die klinische Entwicklung durch einen validierten Prädiktor mit 27 Proteinen zu beschleunigen, der kardiovaskuläre Vorteile in kleineren, kürzeren Studien nachwies.
- SomaScan platform demonstrated capability to analyze 6,400 proteins across 2,000 participants
- Technology validated through publication in prestigious Nature Medicine journal
- Platform shows potential to reduce clinical trial size and duration
- Technology successfully predicted cardiovascular benefits in smaller studies
- None.
Insights
The publication in Nature Medicine represents a substantial validation of Standard BioTools' SomaScan platform in the rapidly expanding GLP-1 therapeutic space. The study's ability to measure 6,400 proteins across 2,000 participants provides unprecedented molecular-level insights into semaglutide's mechanism of action.
The research has three critical implications: First, it validates SomaScan's capability to identify novel drug mechanisms and potential new indications, which could accelerate drug development and expand market opportunities. Second, the 27-protein predictor's ability to detect cardiovascular benefits in smaller studies suggests significant cost and time savings in clinical trials. Third, the platform's reproducibility across two Phase 3 trials strengthens its credibility for pharmaceutical research applications.
For investors, this positions Standard BioTools to potentially capture a larger share of the booming GLP-1 research market, estimated to reach
This development significantly enhances Standard BioTools' competitive position in the proteomics market. The validation from Novo Nordisk, a leading pharmaceutical company in the GLP-1 space, adds substantial credibility to the SomaScan platform. The timing is particularly strategic given the explosive growth in GLP-1 drug development and the rush by pharmaceutical companies to develop similar or improved compounds.
The platform's demonstrated ability to predict cardiovascular outcomes from smaller studies could translate into substantial cost savings for drug developers - potentially reducing the required investment for clinical trials by millions of dollars. This cost-efficiency aspect could drive increased adoption of SomaScan technology across the pharmaceutical industry.
With a current market cap of
Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and expanded drug indications as well as the potential for shorter and smaller clinical trials
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study published in the current issue of Nature Medicine titled “Proteomic changes upon treatment with semaglutide in individuals with obesity”.
Conducted by a team of researchers from Novo Nordisk A/S and collaborators, this seminal paper investigated the effects of semaglutide on the circulating proteome from two independent phase 3 trials. Measuring approximately 6,400 human proteins in nearly 2,000 participants, the study uncovered significant changes in key protein biomarkers associated with metabolic pathways, providing new insights into the biological mechanisms of semaglutide and its potential to have broader health benefits beyond obesity.
“This study exemplifies how advanced proteomic analysis can transform our understanding of therapies in ways that have never been shown before,” said Stephen Williams, MD, PhD, Chief Medical Officer of Standard BioTools. “SomaScan has the unique breadth to uncover the greatest number of actionable insights into complex biological processes, enabling researchers to detect nuanced drug effects earlier, to infer causality of pathways, to deliver highly reproducible results and accelerate the expansion of effective drug indications beyond those initially targeted.”
Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools added, “These findings underscore the vital role of systematic proteomics in advancing precision medicine and improving outcomes for millions of individuals living with obesity and other diseases, firmly aligning with our mission to help pharmaceutical companies make better drugs faster.”
With obesity rates continuing to rise globally, there is increasing interest in developing therapies that address both the condition and its associated health risks, with GLP-1 drugs emerging as the leading option becoming one of the fastest growing and largest drug classes in history. Furthermore, there are many follow-on novel, combinatorial or similar approaches in the pharma pipeline. Semaglutide, a GLP-1 receptor agonist, is a widely used therapeutic for obesity and metabolic disorders, yet its molecular effects on the proteome are not well understood. Using the SomaScan assay, researchers identified changes across hundreds of proteins, offering a deeper understanding of semaglutide’s mode of action and new insights into the biological pathways underpinning its benefits, paving the way for accelerated development of future therapies.
The SomaScan Technology provided the following unique advantages in this breakthrough research:
- Unique Mechanistic Insights: SomaScan revealed specific effects of semaglutide on proteins and pathways, many of which were shown to play a causal role in a variety of indications beyond obesity, as well as insights into additional drug benefits.
- Reliable and Reproducible Results: The SomaScan assay’s precision ensured consistent, quantitative findings across two independent phase 3 studies. Furthermore, many of the mechanistically relevant and potentially causal proteins discovered are not consistently measurable on any other platform.
- Accelerated Clinical Development for Novel Indications: A validated 27-protein predictor (a SomaSignal™ test or SST) of cardiovascular outcomes applied to these studies (STEP 1 and STEP 2) correctly detected previously observed cardiovascular benefits of semaglutide in Novo’s SELECT study, reaching a high degree of statistical significance despite being only a small fraction of its size and duration. This highlights the ability of proteomics to characterize potential or unexpected health benefits earlier, from smaller and shorter clinical studies that were not otherwise powered to detect them.
These findings reinforce the critical role of proteomics in advancing precision medicine and highlight how SomaScan is uniquely capable of driving innovation in drug development.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB) has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future business performance; the breadth and advantages of the SomaScan technology; and market and growth opportunity and potential. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of the merger with SomaLogic, Inc. (“SomaLogic”) and the integration of SomaLogic, including the potential for it to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from the merger with SomaLogic, including the anticipated decrease in operational expenses, at the levels it expects; possible integration, restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the SEC on March 1, 2024, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.
Investor Contact
David Holmes
Gilmartin Group LLC
ir@standardbio.com
FAQ
What was the significance of LAB's SomaScan Platform in the recent Nature Medicine study?
How does LAB's SomaScan technology impact clinical trial efficiency?
What are the key advantages of LAB's SomaScan Platform in drug development?
How did LAB's SomaScan contribute to understanding semaglutide treatment?
